# Neo-Adjuvant Study in Triple Negative Breast Cancer Patients

> **NCT01097642** · PHASE2 · COMPLETED · sponsor: **The Methodist Hospital Research Institute** · enrollment: 40 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Ixabepilone

## Key facts

- **NCT ID:** NCT01097642
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-10
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01097642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01097642, "Neo-Adjuvant Study in Triple Negative Breast Cancer Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01097642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*